CS
RCKT icon

Candriam SCA’s Rocket Pharmaceuticals RCKT Stock Holding History

Candriam SCA’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-165,000
Closed -$4.45M – 717
2024
Q1 		$4.45M Buy
165,000
+55,000
+50% +$1.56M 0.03% 360
2023
Q4 		$3.3M Buy
110,000
+60,000
+120% +$1.32M 0.02% 399
2023
Q3 		$1.02M Hold
50,000
– – 0.01% 551
2023
Q2 		$994K Hold
50,000
– – 0.01% 603
2023
Q1 		$788K Hold
50,000
– – 0.01% 721
2022
Q4 		$978K Buy
+50,000
New +$921K 0.01% 700
2021
Q2 		– Sell
-128,749
Closed -$6.78M – 930
2021
Q1 		$6.78M Hold
128,749
– – 0.06% 321
2020
Q4 		$7.06M Buy
+128,749
New +$4.69M 0.06% 329

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Candriam SCA's RCKT Position: Q2 2024 in Review

Candriam SCA sold out of Rocket Pharmaceuticals (RCKT) in Q2 2024, closing a stake of 165,000 shares — an estimated $4.45M sold.

Candriam SCA first reported a position in RCKT in Q4 2020 and held it in 8 quarters. The position peaked at $7.06M in Q4 2020. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2024.

  • Candriam SCA reported no remaining Rocket Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Candriam SCA sold 165,000 Rocket Pharmaceuticals shares in Q2 2024, an estimated $4.45M.
  • Candriam SCA first reported a position in Rocket Pharmaceuticals in Q4 2020 and held it in 8 quarters.
  • Candriam SCA's Rocket Pharmaceuticals position peaked at $7.06M in Q4 2020.
  • 178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2024.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.